Which neoadjuvant chemotherapy regimen would you use in a young, premenopausal woman with a rapidly growing clinical node positive poorly differentiated TNBC with a germline PALB2 mutation?

My preference is 2) weekly paclitaxel/carboplatin followed by AC, with adjuvant capecitabine if residual disease. There is no doubt that the addition of carboplatin increases the pCR rate in TNBC, and data from GeparSixto and patients on CALGB 40603 in whom doses of paclitaxel/carboplatin were not o...

Although purely speculative, would you add pembrolizumab just because of germline PALB2 mutation and inherent aberration in DNA repair? On similar lines, would platinum and I/O work synergistically in this situation? I hope molecular data from Keynote 522 sheds more light on this aspect.